LAVA Therapeutics Valuation
Is 4PKB undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
3/6Valuation Score 3/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 4PKB when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate 4PKB's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate 4PKB's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 4PKB?
Key metric: As 4PKB is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is 4PKB's PS Ratio? | |
|---|---|
| PS Ratio | 5.7x |
| Sales | US$7.40m |
| Market Cap | US$42.08m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | n/a |
| Enterprise Value/EBITDA | n/a |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does 4PKB's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 6.1x | ||
HPHA Heidelberg Pharma | 12.3x | 16.6% | €103.9m |
2INV 2invest | 8.2x | n/a | €63.8m |
MDG1 Medigene | 3x | 16.1% | €22.6m |
CNW co.don | 0.7x | n/a | €6.5m |
4PKB LAVA Therapeutics | 5.7x | 50.3% | €42.1m |
Price-To-Sales vs Peers: 4PKB is good value based on its Price-To-Sales Ratio (5.7x) compared to the peer average (7.8x).
Price to Sales Ratio vs Industry
How does 4PKB's PS Ratio compare vs other companies in the DE Biotechs Industry?
Price-To-Sales vs Industry: 4PKB is good value based on its Price-To-Sales Ratio (5.7x) compared to the European Biotechs industry average (7.9x).
Price to Sales Ratio vs Fair Ratio
What is 4PKB's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 5.7x |
| Fair PS Ratio | 7.8x |
Price-To-Sales vs Fair Ratio: 4PKB is good value based on its Price-To-Sales Ratio (5.7x) compared to the estimated Fair Price-To-Sales Ratio (7.8x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | €1.49 | €6.64 +345.7% | 30.5% | €10.15 | €5.40 | n/a | 4 |
| Nov ’25 | €1.64 | €6.64 +305.0% | 30.5% | €10.15 | €5.40 | n/a | 4 |
| Oct ’25 | €1.43 | €6.64 +364.4% | 30.5% | €10.15 | €5.40 | n/a | 4 |
| Sep ’25 | €1.52 | €6.64 +336.9% | 30.5% | €10.15 | €5.40 | n/a | 4 |
| Aug ’25 | €1.85 | €6.70 +262.4% | 29.7% | €10.15 | €5.51 | n/a | 4 |
| Jul ’25 | €1.68 | €6.70 +299.0% | 29.7% | €10.15 | €5.51 | n/a | 4 |
| Jun ’25 | €2.06 | €6.69 +224.7% | 29.9% | €10.15 | €5.53 | n/a | 4 |
| May ’25 | €2.64 | €6.70 +153.6% | 30.0% | €10.18 | €5.53 | n/a | 4 |
| Apr ’25 | €2.92 | €6.70 +129.3% | 30.0% | €10.18 | €5.53 | n/a | 4 |
| Mar ’25 | €2.26 | €6.69 +196.0% | 30.0% | €10.16 | €5.51 | n/a | 4 |
| Feb ’25 | €1.50 | €6.67 +344.7% | 29.9% | €10.12 | €5.51 | n/a | 4 |
| Jan ’25 | €1.39 | €6.74 +385.0% | 31.4% | €10.41 | €5.51 | n/a | 4 |
| Dec ’24 | €1.36 | €6.74 +395.7% | 31.4% | €10.41 | €5.51 | n/a | 4 |
| Nov ’24 | €1.10 | €6.75 +513.6% | 31.3% | €10.41 | €5.53 | €1.64 | 4 |
| Oct ’24 | €1.37 | €6.75 +392.7% | 31.3% | €10.41 | €5.53 | €1.43 | 4 |
| Sep ’24 | €1.61 | €5.53 +243.5% | 0.008% | €5.53 | €5.53 | €1.52 | 3 |
| Aug ’24 | €1.68 | €7.14 +324.8% | 23.1% | €9.15 | €5.49 | €1.85 | 4 |
| Jul ’24 | €1.82 | €7.14 +292.1% | 23.1% | €9.15 | €5.49 | €1.68 | 4 |
| Jun ’24 | €1.71 | €11.41 +567.5% | 67.2% | €24.59 | €5.47 | €2.06 | 4 |
| May ’24 | €1.37 | €13.19 +862.7% | 55.8% | €24.59 | €5.47 | €2.64 | 4 |
| Apr ’24 | €1.52 | €13.57 +793.1% | 55.8% | €25.32 | €5.62 | €2.92 | 4 |
| Mar ’24 | €2.04 | €14.24 +598.1% | 48.5% | €25.32 | €5.62 | €2.26 | 5 |
| Feb ’24 | €3.18 | €16.28 +412.1% | 49.9% | €26.05 | €5.70 | €1.50 | 5 |
| Jan ’24 | €3.26 | €16.28 +399.5% | 49.9% | €26.05 | €5.70 | €1.39 | 5 |
| Dec ’23 | €6.25 | €16.39 +162.3% | 49.2% | €26.05 | €5.84 | €1.36 | 5 |
| Nov ’23 | €4.36 | €17.19 +294.2% | 49.6% | €29.03 | €6.22 | €1.10 | 5 |
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.
Discover undervalued companies
Amneal Pharmaceuticals
US$2.6b
Develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide.
2DT
US$7.70
7D
-4.3%
1Y
91.5%
Teva Pharmaceutical Industries
US$19.4b
Develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally.
TEV
US$16.25
7D
2.5%
1Y
89.8%
Merck
US$252.6b
Operates as a healthcare company worldwide.
6MK
US$97.10
7D
6.7%
1Y
3.9%